Evaluation of new gastro-intestinal prokinetic (ENGIP-I) study.
The ENGIP-I study was conducted to investigate the efficacy, and safety of itopride in patients of gastro-oesophageal reflux disease. There were significant reductions in heartburn frequency, heartburn severity, gastro-oesophageal regurgitation frequency at day 3 only. ENGIP-I study concluded that itopride was well tolerated by patients and appears to be the drug of choice in patients with gastro-oesophageal reflux disease.
JB Chemicals & Pharmaceuticals Limited, Mumbai 400030.
Pradeep P
PP
Walwaikar
Sujay S
SS
Kulkarni
Rahul S
RS
Bargaje
D000293:Adolescent; D000328:Adult; D000368:Aged; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D001593:Benzyl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects*; D005764:Gastroesophageal Reflux / Q000188:drug therapy* / Q000503:physiopathology; D006356:Heartburn / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D007194:India; D008297:Male; D008875:Middle Aged; D012449:Safety; D016896:Treatment Outcome
D001549:Benzamides; D001593:Benzyl Compounds; C102254:itopride